
Daniel Mikol, MD, PhD, vice president of Neuroscience Development at AbbVie, discussed how precision tools, AI, and patient partnership are reshaping the design and execution of modern neuroscience clinical trials.

Daniel Mikol, MD, PhD, vice president of Neuroscience Development at AbbVie, discussed how precision tools, AI, and patient partnership are reshaping the design and execution of modern neuroscience clinical trials.